🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Distribution of Lymph Node Metastases in Esophageal Carcinoma

Recruitingn/aAges 18 Years - anyAllAcademisch Medisch Centrum - Universiteit van Ams…
NCT03222895 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background: Lymph node status is an important prognostic parameter in esophageal carcinoma and an independent predictor of survival. Distribution of metastatic lymph nodes may vary with tumor location, tumor histology, tumor invasion depth and neoadjuvant therapy. Surgical strategy depends on the distribution pattern of nodal metastases but consensus on the extent of lymphadenectomy differs worldwide. Especially for adenocarcinoma the distribution of lymph node metastases has not yet been described in large series. Aim of the present study is to evaluate the distribution of lymph node metastases in esophageal carcinoma specimens following transthoracic esophagectomy with at least a 2-field lymphadenectomy. Methods: The TIGER-study is a multinational observational cohort study. All patients with a resectable esophageal or gastro-esophageal junction carcinoma in whom a transthoracic esoph

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Primary squamous cell or adenocarcinoma of the esophagus or esophago-gastric junction * Surgically resectable (cT1-4a, N0-3, M0) * Adequate physical condition to undergo transthoracic surgery (ASA 1-3) * Transthoracic esophagectomy Exclusion Criteria: * Previous thoracic or abdominal (upper GI) surgery disturbing lymph drainage of the esophagus and stomach * Patients with in situ carcinoma or high grade dysplasia
💊

What it tests

  • Not listed
📍

Where

19 sites
MD Anderson Cancer Center
Houston, United States
Instituto Nacional de Câncer
Rio de Janeiro, Brazil
University of Toronto
Toronto, Canada
Fudan University Shanghai Cancer Center
Shanghai, China
Hospital District of Helsinki and Uusimaa
Helsinki, Finland
University Medical Center of the Johannes Gutenberg University
Mainz, Germany
University of Athens, School of Medicine
Athens, Greece
University of Hong Kong
Hong Kong, Hong Kong

…and 11 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy